Sinobiopharma Announces SFDA Approval of Anti-Hypertension Drug Perindopril

Name	Symbol	Market	Type
SNCF Mobilites Medium-term Notes 1.10% until 25may31	EU:SNBP	Euronext	Bond

SNCF Mobilites Medium-te... (EU:SNBP)
Historical Stock Chart

From Jul 2019 to Jul 2024

Click Here for more SNCF Mobilites Medium-te... Charts.

NANTONG CITY, China, May 11 /PRNewswire-FirstCall/ -- Sinobiopharma, Inc. (OTC:SNBP) (BULLETIN BOARD: SNBP) ("Sinobiopharma" or, the "Company") is pleased to announce that it has received approval from the Chinese State Food and Drug Administration (SFDA) to manufacture and market its formulation of Perindopril, an anti-hypertension drug. Perindopril, used alone or in combination with other medications to treat high blood pressure, is the latest generation of a class of medications called angiotensin-converting enzyme (ACE) inhibitors. It supports circulation by preventing the production of chemicals that occur naturally in the body but constrict blood vessels. As the first Chinese producer of Perindopril, Sinobiopharma comes to market with significant competitive advantages, including lower cost active pharmaceutical ingredients (API), and being the first in the world to offer capsule formulation, which is not only easier to swallow, but also has greater efficacy and reduced side effects compared to earlier versions of the drug. Prior to SFDA approval of Sinobiopharma's version, Servier (France) was the only firm to market Perindopril in China. Perindopril completed clinical trials in September 2007. High blood pressure is a leading cause of stroke, heart attack and kidney failure; it affects an estimated one billion people worldwide. In China, the incidence of cardiovascular and cerebrovascular diseases is on the rise, costing patients approximately RMB 300 billion (US $37 billion) in medical expenses each year. Of this amount, some RMB 30 billion (US $3.7 billion) is spent directly on the treatment of hypertension, according to China's Ministry of Health. High blood pressure affects nearly one in five Chinese adults during their lifetime, according to the State Council of China. "SFDA approval of Sinobiopharma's formulation of Perindopril strengthens our product portfolio in keeping with our strategy of focusing on first-to-market generic and innovative drugs," says Lequn Huang, Company President and CEO. About Sinobiopharma Sinobiopharma, Inc. is a fully integrated and highly innovative biotechnology company engaged in the research and development, manufacture and marketing of biopharmaceutical products in China, the world's fastest growing pharmaceutical market. Known as Dong Ying (Jiangsu) Pharmaceutical Co. Ltd. in China, the Company's current therapeutic focus is on anesthesia-assisted agents and cardiovascular drugs. Contacts: Sinobiopharma, Inc. Investor Relations 1-877-568-0188 FORWARD-LOOKING STATEMENTS This news release may include "forward-looking statements" regarding Sinobiopharma, Inc., and its subsidiaries, business and project plans. Such forward-looking statements are within the meaning of Section 27A of the Securities Act of 1933, as amended, and section 21E of the United States Securities and Exchange Act of 1934, as amended, and are intended to be covered by the safe harbor created by such sections. Where Sinobiopharma, Inc. expresses or implies an expectation or belief as to future events or results, such expectation or belief is believed to have a reasonable basis. However, forward-looking statements are subject to risks, uncertainties and other factors, which could cause actual results to differ materially from future results expressed, projected or implied by such forward-looking statements. Sinobiopharma, Inc. does not undertake any obligation to update any forward-looking statement, except as required under applicable law. DATASOURCE: Sinobiopharma, Inc. CONTACT: Investor Relations of Sinobiopharma, Inc., 1-877-568-0188 Web Site: http://www.sinobiopharma.com/

Market Data

News

Trading Tools

Markets

Discover

Hot Features

Follow Feed

Options Flow

Monitor

SNBP SNCF Mobilites Medium-term Notes 1.10% until 25may31